Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

J Thromb Thrombolysis. 2020 Nov;50(4):833-836. doi: 10.1007/s11239-020-02244-y.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects*
  • Hemorrhage / chemically induced*
  • Hemorrhage / epidemiology
  • Host-Pathogen Interactions
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Prevalence
  • Risk Factors
  • SARS-CoV-2
  • Switzerland / epidemiology
  • Thrombosis / epidemiology
  • Thrombosis / prevention & control*
  • Thrombosis / virology
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Anticoagulants
  • Fibrinolytic Agents